or Try an Advanced Search...

    Technical Analysis for DNLI - Denali Therapeutics Inc.

    Grade Last Price % Change Price Change
    F 15.43 3.14% 0.47
    DNLI closed up 3.14 percent on Friday, April 26, 2024, on 86 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 6
    *** please verify all earnings dates ***
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical DNLI trend table...
    Date Alert Name Type % Chg
    Slingshot Bearish Bearish Swing Setup 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    New 52 Week Closing Low Bearish 3.14%
    New 52 Week Low Weakness 3.14%
    Wide Bands Range Expansion 3.14%
    Gapped Down Weakness 3.14%
    Lower Bollinger Band Touch Weakness 3.14%
    Oversold Stochastic Weakness 3.14%
    New 52 Week Closing Low Bearish -0.84%
    Older End-of-Day Signals for DNLI ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 20 hours ago
    Up 3% about 20 hours ago
    Up 2% about 20 hours ago
    Up 1% about 21 hours ago
    Down 5% 2 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    DNLI Chart by TradingView
    Basic chart:

    Profile

    Denali Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing therapeutics for neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Organ Systems Neuroscience Alzheimer's Disease Parkinson's Disease Neurological Disorders Neurodegenerative Diseases Amyotrophic Lateral Sclerosis Degenerative Disease Neurodegeneration Senescence

    Is DNLI a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 9 Why Denali Therapeutics (DNLI) Stock Might be a Great Pick
    Mar 29 Sarepta Therapeutics (SRPT) Up 1.2% Since Last Earnings Report: Can It Continue?
    Mar 28 Why Is Denali Therapeutics (DNLI) Up 2.8% Since Last Earnings Report?
    Mar 22 Denali Therapeutics files to sell 29.29M shares of common stock for holders
    Mar 19 Further weakness as Denali Therapeutics (NASDAQ:DNLI) drops 7.4% this week, taking three-year losses to 67%
    Mar 7 Denali: Leveraging Transport Vehicle Technology For Neurological Gains
    Feb 28 Denali's (DNLI) Q4 Earnings Miss, Pipeline in Focus, Stock Up
    Feb 27 Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Feb 27 Denali spikes after $500M private placement
    Feb 27 Denali Therapeutics GAAP EPS of -$0.86
    See more DNLI news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 33.31
    52 Week Low 14.56
    Average Volume 1,297,862
    200-Day Moving Average 20.71
    50-Day Moving Average 18.96
    20-Day Moving Average 17.73
    10-Day Moving Average 16.27
    Average True Range 0.88
    RSI (14) 32.43
    ADX 24.79
    +DI 16.60
    -DI 37.86
    Chandelier Exit (Long, 3 ATRs) 18.40
    Chandelier Exit (Short, 3 ATRs) 17.20
    Upper Bollinger Bands 21.01
    Lower Bollinger Band 14.45
    Percent B (%b) 0.15
    BandWidth 37.00
    MACD Line -1.13
    MACD Signal Line -0.85
    MACD Histogram -0.288
    Fundamentals Value
    Market Cap 2.13 Billion
    Num Shares 138 Million
    EPS -0.94
    Price-to-Earnings (P/E) Ratio -16.41
    Price-to-Sales 7.32
    Price-to-Book 2.23
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 16.32
    Resistance 3 (R3) 16.24 15.86 16.17
    Resistance 2 (R2) 15.86 15.64 15.90 16.12
    Resistance 1 (R1) 15.65 15.50 15.76 15.73 16.07
    Pivot Point 15.27 15.27 15.33 15.31 15.27
    Support 1 (S1) 15.06 15.05 15.17 15.14 14.79
    Support 2 (S2) 14.68 14.91 14.72 14.74
    Support 3 (S3) 14.47 14.68 14.69
    Support 4 (S4) 14.55